TriSalus Life Sciences, Inc. (TLSI) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 11.17M USD | Liabilities, Current |
| Cash and equivalents | 46.29M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 6.46M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 4.21M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $11.17M | $46.29M | (m) | $6.46M | $4.21M | (m) |
| 2026-03-31 | (m) | $11.79M | $56.55M | (m) | $5.21M | $3.78M | (m) |
| 2025-12-31 | (m) | $11.50M | $20.44M | (m) | $6.56M | $3.08M | (m) |
| 2025-09-30 | (m) | $10.91M | $22.69M | (m) | $5.00M | $3.28M | (m) |
| 2025-06-30 | (m) | $9.32M | $26.49M | (m) | $5.57M | $3.81M | (m) |
| 2025-03-31 | (m) | $11.75M | $13.00M | (m) | $5.45M | $4.16M | (m) |
| 2025-01-01 | (m) | (m) | (m) | (m) | $5.10M | (m) | (m) |
| 2024-12-31 | (m) | $10.23M | $8.53M | (m) | $5.09M | $4.05M | (m) |
| 2024-09-30 | (m) | $9.92M | $11.29M | (m) | $4.91M | $4.00M | (m) |
| 2024-06-30 | (m) | $12.00M | $16.48M | (m) | $4.71M | $3.44M | (m) |
| 2024-03-31 | (m) | $14.39M | $3.97M | (m) | $4.28M | $2.91M | (m) |
| 2024-01-01 | (m) | (m) | (m) | (m) | $3.60M | (m) | (m) |
| 2023-12-31 | (m) | $14.69M | $11.78M | (m) | $3.55M | $2.54M | (m) |
| 2023-09-30 | (m) | $9.30M | $21.38M | (m) | $3.05M | $1.63M | (m) |
| 2023-06-30 | (m) | $6.03M | $103.97K | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $4.66M | $136.80K | (m) | (m) | (m) | (m) |
| 2023-01-01 | (m) | (m) | (m) | (m) | $1.60M | (m) | (m) |
| 2022-12-31 | (m) | $2.50M | $153.56K | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $1.91M | $207.60K | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $1.74M | $69.18K | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $2.08M | $50.93K | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | $200.88K | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | $277.81K | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | $642.94K | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | $1.13M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | $1.33M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |